Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Tumor-Treating Fields in Recurrent Glioblastoma
NCT04221503Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Dec 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in glioblastoma (GBM), sponsored by Abramson Cancer Center. Started Dec 2019; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04221503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221503.